Search results
Results from the WOW.Com Content Network
Primary myelofibrosis (PMF) is a rare bone marrow blood cancer. [1] It is classified by the World Health Organization (WHO) as a type of myeloproliferative neoplasm , a group of cancers in which there is activation and growth of mutated cells in the bone marrow .
The most common symptoms are bleeding (due to dysfunctional platelets), blood clots (e.g., deep vein thrombosis or pulmonary embolism), fatigue, headache, nausea, vomiting, abdominal pain, visual disturbances, dizziness, fainting, and numbness in the extremities; the most common signs are increased white blood cell count, reduced red blood cell ...
Acute panmyelosis with myelofibrosis (APMF) is a poorly defined disorder that arises as either a clonal disorder, or following toxic exposure to the bone marrow. [ 1 ] Signs and symptoms
Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.
Prefibrotic primary myelofibrosis (Pre-PMF) is a rare blood cancer, classified by the World Health Organization as a distinct type of myeloproliferative neoplasm in 2016. [1] The disease is progressive to overt primary myelofibrosis , though the rate of progression is variable and not all patients progress.
Intrinsically related symptoms such as fever, malaise, pruritus (itching) due to the release of histamine, [5] fatigue, and right upper quadrant pain may be present in the afflicted patient. With some conditions, such as polycythemia vera , erythromelalgia , or burning of the palms and soles, coupled with thrombocytosis is common.
Histopathological image representing a bone marrow aspirate in a patient with essential thrombocythemia. In hematology, thrombocythemia is a condition of high platelet (thrombocyte) count in the blood.
The goals of therapy are to control symptoms, improve quality of life, improve overall survival, and decrease progression to AML. The IPSS scoring system can help guide therapy for patients with MDS. [ 43 ] [ 44 ] In those with low risk MDS (designated by an IPSS score less than 3.5), no disease specific treatment has been found to be helpful ...